Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of Fulvestrant (Faslodex) with or without pd-0332991 (Palbociclib) +/- Goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy

Project: Research

Project Details

Project Description

Monash Health HREC Ref: 14094X
Effective start/end date29/03/1928/03/24


  • clinical trial
  • treatment efficacy
  • breast cancer
  • endocrine therapy